Targeted delivery of lupeol via hyaluronic acid-modified ZIF-8 for anti-hepatic fibrosis therapy.

Hepatic fibrosis (HF), a common pathological consequence of chronic liver injury, is driven by the excessive proliferation and activation of hepatic stellate cells (aHSCs). Non-alcoholic steatohepatitis, the inflammatory form of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease, NAFLD), serves as a key driver of the HF process. Although previous studies have found that lupeol can act as an FXR-agonist to ameliorate MASLD through the FXR-SHP pathway, its therapeutic potential is severely limited by drawbacks such as poor solubility, low stability, rapid degradation, insufficient targeting specificity, collectively constrain its therapeutic potential. To overcome these limitations, we developed the HA/Lupeol@ZIF-8-a dual-functional nano-delivery system combining CD44-targeting and pH-responsive drug release. It encapsulates the FXR-agonist lupeol in ZIF-8 framework and is surface-modified with hyaluronic acid to allow for active targeting of CD44-highly-expressing aHSCs. In the acidic-fibrotic microenvironment, ZIF-8 undergoes pH-responsive degradation, enabling precise release of both the lupeol and Zn